

Mediq Danmark A/S

Kornmarksvej 15-19
2605 Brøndby
Denmark

CVR no. 86 47 99 15

Annual report 2022

The annual report was presented and approved at
the Company's annual general meeting on

29 June 2023

Philip Mørch Nadelmann
Chairman



Contents

Statement by the Board of Directors and the Executive Board	2
Independent auditor's report	3
Management's review	5
Company details	5
Financial highlights	6
Operating review	7
Financial statements 1 January – 31 December	12
Income statement	12
Balance sheet	13
Statement of changes in equity	15
Notes	16

Statement by the Board of Directors and the Executive Board

The Board of Directors and the Executive Board have today discussed and approved the annual report of Mediq Danmark A/S for the financial year 1 January – 31 December 2022.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2022 and of the results of the Company's operations for the financial year 1 January – 31 December 2022.

Further, in our opinion, the Management's review gives a fair review of the development in the Company's activities and financial matters, of the results for the year and of the Company's financial position.

We recommend that the annual report be approved at the annual general meeting.

Brøndby, 29 June 2023
Executive Board:



Katrine Bjarkov Benthien

Board of Directors:



Philip Mørch Nadelmann
Chairman



Robert Paul Janse



Katrine Bjarkov Benthien

Independent auditor's report

To the shareholder of Mediq Danmark A/S

Opinion

We have audited the financial statements of Mediq Danmark A/S for the financial year 1 January – 31 December 2022 comprising income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2022 and of the results of the Company's operations for the financial year 1 January – 31 December 2022 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users made on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also

- identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

Independent auditor's report

- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 29 June 2023

KPMG

Statsautoriseret Revisionspartnerselskab

CVR no. 25 57 81 98



State Authorised
Public Accountant
mne42778

Mediq Danmark A/S
Annual report 2022
CVR no. 86 47 99 15

Management's review

Company details

Mediq Danmark A/S
Kornmarksvej 15-19
2605 Brøndby
Denmark

Telephone: +45 36 37 91 00
Website: www.mediqdanmark.dk

CVR no.: 86 47 99 15
Established: 30 April 1979
Registered office: Brøndby
Financial year: 1 January – 31 December

Board of Directors

Philip Mørch Nadelmann, Chairman
Robert Paul Janse
Katrine Bjarkov Benthien

Executive Board

Katrine Bjarkov Benthien

Auditor

KPMG
Statsautoriseret Revisionspartnerselskab
Dampfærgevej 28
DK-2100 København Ø
CVR no. 25 57 81 98

Management's review

Financial highlights

DKK'000	2022	2021	2020	2019	2018
Key figures					
Revenue	727,630	786,101	1,079,490	705,820	729,778
Gross profit	171,107	183,811	184,657	148,515	130,273
Profit before financial income and expenses	51,468	72,864	73,060	35,750	23,084
Net financials	2,534	3,902	1,164	1,853	-420
Profit/loss for the year	39,643	59,366	57,741	26,172	16,703
Balance sheet					
Total assets	378,322	357,086	361,298	256,151	236,107
Equity	178,442	180,799	152,461	120,720	110,548
Investment in property, plant and equipment	6,914	3,961	3,806	3,101	4,251
Ratios					
Gross margin	23.5%	23.4%	17.1%	21.0%	17.9%
Profit margin	7.1%	9.3%	6.8%	5.1%	3.2%
Return on assets	13.6%	18.3%	0.6%	0.4%	8.9%
Solvency ratio	47.2%	50.6%	42.2%	47.1%	46.1%
Employees					
Average number of full- time employees	194	177	182	176	168

The financial ratios have been calculated as follows:

Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios "Recommendations & Ratios".

In 2019, Mediq Danmark A/S has acquired Puls Danmark A/S. After the acquisition the Company has merged with Mediq Danmark A/S. Mediq Danmark A/S is the continuing Company in the merger.

The key figures and financial ratios above are not fully comparable within the five years due to the mergers in 2019.

In 2021, Mediq Danmark A/S has acquired Upviser ApS. After the acquisition the company has merged with Mediq Danmark A/S. Mediq Danmark A/S is the continuing company in the merger.

The key figures and financial ratios above are not fully comparable within the five years due to the mergers in 2021

The financial ratios have been calculated as follows:

Gross margin

$$\frac{\text{Gross profit} \times 100}{\text{Revenue}}$$

Profit margin

$$\frac{\text{Profit before net financials} \times 100}{\text{Revenue}}$$

Return on assets

$$\frac{\text{Profit before net financials} \times 100}{\text{Total assets}}$$

Solvency ratio

$$\frac{\text{Equity at year end} \times 100}{\text{Total assets}}$$

Management's review

Operating review

Core activity

The Company's activities comprise trade in hospital and healthcare products for the social and health sectors.

Development in activities and financial position

The income statement of the Company for 2022 shows a profit of DKK 39.643 thousand and at 31 December 2022, the balance sheet of the Company showed an equity of DKK 178.442 thousand.

The Company's results and financial development were satisfactory.

Financial instruments

The Company's risk exposure

The Company's risks are considered moderate, as several different customer segments and a large part of revenue is based on tenders.

A minor part of the Company's purchases is made in foreign currencies. Thus, the foreign exchange risk is considered moderate. The Company does not enter into foreign exchange positions for speculative purposes but may choose to mitigate risk exposure through foreign currency hedges.

The Company's interest rate risk is assessed to be minimal since the Company is self-funding.

Corporate social responsibility and business model

Mediq is a trusted partner in healthcare, helping people to live their lives to the fullest potential by providing good and affordable healthcare products.

Our vision on global changes in healthcare

We stand today at the brink of unparalleled demographic shifts that threaten assumptions of entitlement to treatment. Rapidly ageing populations and an accelerating incidence of chronic disease have far-reaching implications for healthcare and pose enormous challenges - for us and for society.

At Mediq, we believe access to healthcare is a social right, but it is not a given. It can only be achieved if we continue to seek and develop new and innovative solutions that drive change for the better and improve patient outcomes.

With our knowledge, expertise and international network comes great responsibility. We have the biggest impact when we bring our scale to bear on solving healthcare's biggest challenges: bringing together government, municipalities and healthcare professionals to create new solutions and approaches in treatments, care processes and logistics.

Environmental and climate considerations

Protecting the environment is the right thing to do. We comply with all applicable environment-related rules and regulations and aspire to adopt "best practices" in environmental procedures and standards. While our own operations have a relatively low impact on the environment, we are alert to opportunities to reduce our environmental impact in areas where we have the greatest influence. These have been defined as packaging, waste, internal processes using water, district heating and electricity and lease car policy. One of the pillars of Media's approach to reducing environmental impact is responsible procurement and sourcing. Therefore, external transportation is in focus for lowering CO2 emission.

Management's review

Operating review

We distribute medical devices to hospitals, healthcare institutions as well as directly to patients. CO2 emissions from transport therefore represent a significant part of Mediq's environmental impact. To cut emissions we encourage customers to increase order size and thereby order less times, which has been a success.

Our internal policies are focusing on minimizing our CO2 emission until 2026.

- Green car policy, where the preferred company car is an electric car. In 2022 we have established charging stations at the premises.
- Consumption from internal processes using water, district heating and electricity. The goal is to reduce the total CO2 by 5%
- Mediq's ambition in the Waste Management policy is 75% recycle from all fractions (In 2022, we achieved our goal of 75% and want to maintain that level). All employees are educated in waste handling as part of their onboarding training waste academy.
- Environmental system measures CO2 pollution figures from external transportation per month to follow development.
- We only purchase electricity coming from European windmills documented by RECS certificates..

Mediq will continue to work with the environment and climate to minimize the CO2 emission.

Social and employee relations

In the Mediq Code of Conduct key principles are described to ensure that in Mediq we do the right thing in the right way. The Code of Conduct is presented to all new employees during onboarding. This Code is applicable to all employees, officers and directors (together. "Employees") of Mediq and governs all our decisions and actions, whether in our offices, warehouses, in the boardroom, at customer or supplier premises or when providing care to our patients. This Code of Conduct is at the center of everything we do. It reinforces our Core Values. Through a transparent performance management process, we aim to create a working environment in which employees feel challenged, where they can develop their skills and competences and be successful.

In Mediq we aim to provide a working environment that is free from harassment of any kind and/or any other offensive or disrespectful conduct and have a zero-tolerance policy regarding workplace violence. Mediq is committed to upholding ethical labor practices and procedures. Our responsibility in this area includes creating awareness and understanding of human rights, as well as employment and labor practices. By incorporating these principles into strategies, policies and procedures, and living out our values; Caring Heart, Customer Drive, Champion Spirit, Mediq will uphold our basic responsibilities to our people, our environment, and set the stage for our long-term success.

In our human resource policy, the following issues are key:

Diversity

We employ people who come from an even wider range of nationalities. We want everybody to feel at home in Mediq and have the same opportunities, irrespective of nationality, race, gender, sexual orientation, age, religion and handicap. It is Mediq's ambition to have a balanced gender distribution and equal pay for equal work. Approximately 50% of Mediq's employees are women.

Management's review

Operating review

Gender Diversity in the Management prepared according to Danish Financial Statements Act §99b

Our goal is to have an equal gender distribution, but new members of staff/Board of Directors are recruited exclusively on the basis of their qualifications. In middle and top management, 50% are women. One woman is represented on the Board of Directors, which consists of three members. As these distributions fulfill the requirements for an equal distribution of gender (60/40) we have not set a target for increasing the number of women on the Board of Directors or formulated a policy for increasing the number of women in management. However, we continuously work to uphold the equal distribution.

Recruitment and retention

Mediq aims to attract capable people who want to work in a company that combines healthcare and entrepreneurial drive. We seek employees who are flexible, ambitious and passionate about working in the healthcare business, and who act in alignment with our core values. Our recruitment process is in line with GDPR standards, and we always strive to find a match in recruitment processes. We aim at successful recruitments by keeping turnover in new hires at a minimum during the first two years. The turnover rate of employees in general varies according to the development in the Danish labor market development. The employee turnover rate in 2022 was above the aim of approximately 10-13%. The turnover rate is a risk as in many similar companies, which we continuously monitor.

Engagement

Our ambition is to have committed and proud employees who identify with the Company's strategy. Therefore, we continuously strive to increase engagement among employees, through a transparent communication with an interactive social platform which makes it easy to market social gatherings. employee "stay strong" initiatives, training and education and all together strengthening a positive cross department working culture.

Feedback regarding working environment is continuously received from employees through engagement surveys and workplace evaluations (APV) conducted at a minimum by-annually. Employee feedback is key to improving our organization.

Development

As an international company present in 13 countries across Europe, opportunities exist to learn cross border and develop through cross-border job responsibilities. Focus on development is part of the annual performance management process. In Mediq, we take on our social responsibility to train trainees and students. In several departments, we have student assistants and trainees engaged in order to gain practical experience in combination with the theoretical studies. In addition, we co-operate with local municipalities in engaging local citizens as interns returning to the labor market from e.g long-term illness or finding a foothold in the Danish labor market, we aim at fulfilling our social responsibility here.

Health and safety

Mediq has safety procedures and carries them out conscientiously. These procedures are described in handbooks and quality systems. Safety training is used to educate logistics employees. Local Working Environment Representatives are proactively conducting audits to secure and satisfy ongoing need for training to have a safe and healthy working environment at all times. In Mediq, we look at our rate of absenteeism as a measurement of our working environment. We aim at having an absenteeism percentage at a maximum of 4.0% across the company on average throughout the year. In 2022, the average was 4.7% and hence in align with goal.

In order to support employees in healthy recovery, a permanent employment in Mediq includes membership of private healthcare insurance supporting health initiatives and recovery. Further to this, Mediq continuously has an occupational therapist conducting training on a continuous basis combined with access to own fitness center and training on site.

In line with our Code of Conduct, we have an integrity procedure in place. This can be done via a special telephone line or the internet ("Whistleblowing system).

Management's review

Operating review

The employee retention and engagement are managed through engagement surveys and workplace evaluations (APV)

Human and labour rights

Mediq supports and respects the protection of internationally proclaimed human rights, and we strive to ensure that we are not complicit in human rights abuses. We also uphold the freedom of association and the effective recognition of the right to collective bargaining, the elimination of all forms of forced and compulsory labor, and the effective abolition of child labor.

We are committed to upholding ethical labor practices and support and respect the protection of internationally proclaimed human rights as laid down in UN and ILO conventions.

We have not at any time experienced breaches of human rights in connection with the exercise of our business or assessed a nearby risk thereof. The risk of breaches of human rights is limited by the fact that we only have activities in Denmark and we select suppliers, third party representatives and other business partners based on their qualifications, reliability and adherence to applicable laws and our values. We take reasonable care in selecting them and do appropriate reviews from time to time. We require that they commit to adhering to the law and our Code of Conduct and that they have the training and tools to do so, and that they shall be able to document their efforts to secure compliance with the law and our Code of Conduct at our request. This also applies to any sub-supplier. Mediq may terminate the relationship with any supplier, third party representative or other business partner that fails to meet the standards in Code of Conduct after a reasonable period of time for remedying a breach.

Skills, performance and ethical conduct are our only indicators of employee qualifications.

We expect to continue our work on human rights in the future.

Anti-corruption and bribery

Bribery and corruption damage our business and conflict with our core beliefs regarding the right way to conduct business. We prohibit bribery and corruption, none of us or anyone acting on our behalf may accept offer or pay a bribe, kickback or other improper payment. We are also not allowed to accept or provide anything of value that is intended to win business, improperly influence a decision, or gain an unfair business advantage - or even appear to do so. Examples of "anything of value" may include, among other things, sponsorships to attend congresses, speaking fees, consultancies, services, charitable donations, political contributions, travel and/or entertainment expenses, gifts, meals, commissions and rebates.

The main risks related to our activities include employees' and suppliers' violation of Mediq's Code of Conduct and potential legal and financial consequences hereof. The Code of Conduct is presented to all new employees during onboarding and to all new suppliers when commencing cooperation.

Our business activities are subject to various national laws and regulations.

In 2022, we have not seen any violations of the policy. We continue our focus in 2023 and forward. We will not accept any corruption or bribery.

Management's review

Operating review

Data ethics

At Mediq dataethics is an important matter. We have two policies in place that outlines our approach to dataethics. These policies state that all employees, contractors, consultant, temporary and other workers must adhere to our policy and ensure that:

- Mediq resources are not used for any unlawful or prohibited purpose
- Data are handled according to our data classification policy
- Any security or privacy breaches are reported
- Mediq information assets are managed responsibly to ensure confidentiality, integrity, and availability

We collect and hold necessary data to serve our customers and comply with GDPR legislation. No data are bought or sold to third parties. In order to ensure compliance with our policy we have authorized personnel that monitor and audit our systems and network traffic. Furthermore, we classify all our data based on risk and quality measures. This classification system is implemented in order to ensure that sensitive information is handled according to the risk it poses to the organization. In case an employee or contractor violate our policy they may be subject to disciplinary actions, that could result in dismissal or termination of contract.

Subsequent events

No subsequent events have occurred after the end of the financial year that might materially affect the Company's financial position.

Outlook

Management expects a decrease in the public procurement budgets as well as additional consolidation of Procurement which may affect revenue and performance in 2023.

Financial statements 1 January – 31 December

Income statement

DKK'000	Note	2022	2021
Revenue	2	727,630	786,101
Cost of sales		-478,567	-527,836
Other external costs		<u>-77,956</u>	<u>-74,454</u>
Gross profit		171,107	183,811
Staff costs	3	-111,643	-104,621
Depreciation, amortisation and impairment losses of intangible assets and property, plant and equipment	4	<u>-7,996</u>	<u>-6,326</u>
Profit before financial income and expenses		51,468	72,864
Financial income	5	3,284	4,681
Financial expenses	6	<u>-750</u>	<u>-779</u>
Profit before tax		54,002	76,766
Tax on profit for the year	7	<u>-14,359</u>	<u>-17,400</u>
Profit for the year	8	<u><u>39,643</u></u>	<u><u>59,366</u></u>

Financial statements 1 January – 31 December

Balance sheet

DKK'000	Note	31/12 2022	31/12 2021
ASSETS			
Fixed assets			
Intangible assets	9		
Customer relations		995	1,661
Goodwill		32,811	36,039
Development projects in progress		41,433	29,862
		<u>75,239</u>	<u>67,562</u>
Property, plant and equipment	10		
Fixtures and fittings, tools and equipment		12,779	7,143
Leasehold improvements		3,121	2,203
Property, plant and equipment in progress		2,744	2,892
		<u>18,644</u>	<u>12,238</u>
Investments			
Deposits		4,107	4,006
Total fixed assets		<u>97,990</u>	<u>83,806</u>
Current assets			
Inventories			
Finished goods and goods for resale		77,575	77,881
Receivables			
Trade receivables		91,390	110,811
Receivables from group entities		110,013	80,935
Other receivables		658	1,091
Deferred tax asset	11	696	536
Prepayments	12	0	66
		<u>202,757</u>	<u>193,439</u>
Cash at bank and in hand	13	0	1,960
Total current assets		<u>280,332</u>	<u>273,280</u>
TOTAL ASSETS		<u><u>378,322</u></u>	<u><u>357,086</u></u>

Financial statements 1 January – 31 December

Balance sheet

DKK'000	Note	31/12 2022	31/12 2021
EQUITY AND LIABILITIES			
Equity			
Contributed capital	14	5,010	5,010
Other reserves		9,025	0
Reserve for development costs		23,292	23,292
Retained earnings		91,115	110,497
Proposed dividends for the financial year		50,000	42,000
Total equity		178,442	180,799
Liabilities			
Current liabilities			
Trade payables		95,462	90,764
Payables to group entities		70,848	46,803
Other payables		33,570	38,720
		199,880	176,287
Total liabilities		199,880	176,287
TOTAL EQUITY AND LIABILITIES		378,322	357,086
Fees to auditor appointed at the general meeting			
Contractual obligations, contingencies, etc.	15		
Related party disclosures	16		
Financial Instruments	17		

Financial statements 1 January – 31 December

Statement of changes in equity

DKK'000	Contributed capital	Other reserves	Reserve for development costs	Retained earnings	Proposed dividends for the financial year	Total
Equity at 1 January 2022	5,010	0	23,292	110,497	42,000	180,799
Ordinary dividends paid	0	0	0	0	-42,000	-42,000
Transferred over the profit appropriation	0	9,025	0	-19,382	50,000	39,643
Equity at 31 December 2022	5,010	9,025	23,292	91,115	50,000	178,442

Financial statements 1 January – 31 December

Notes

1 Accounting policies

The annual report of Mediq Danmark A/S for 2022 has been prepared in accordance with the provisions applying to reporting class C large entities under the Danish Financial Statements Act.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

Omission of cash flow statement

Pursuant to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The Company's cash flows are included in the cash flow statement in the consolidated financial statements of Mediq Top Holding B.V.

Omission of auditor's fee

Pursuant to section 96(3) of the Danish Financial Statements Act, no disclosure of auditor's fee has been prepared. The Company's disclosure of the auditor's fee is included in the consolidated financial statements of Mediq Top Holding B.V.

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or expenses.

Receivables, payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and at the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or expenses.

Fixed assets acquired in a foreign currency are translated at the exchange rate prevailing on the transaction date.

Derivative financial instruments

On initial recognition, derivative financial instruments are recognised in the balance sheet at cost and subsequently measured at fair value. Positive and negative fair values of derivative financial instruments are recognised as other receivables and other payables, respectively.

Changes in the fair value of derivative financial instruments designated as or qualifying for recognition as a fair value hedge of a recognised asset or liability are recognised in the income statement together with changes in the fair value of the hedged asset or liability.

For derivative financial instruments not qualifying for treatment as hedging instruments, changes in fair value are recognised in the income statement on an ongoing basis.

Financial statements 1 January – 31 December

Notes

1 Accounting policies (continued)

Income statement

Revenue

Income from the sale of goods for resale and finished goods is recognised in revenue when delivery and transfer of risk to the buyer have taken place before year-end, and the income can be reliably measured and is expected to be received.

Revenue is measured at the fair value of the agreed remuneration, excluding VAT and taxes charged on behalf of third parties. All discounts granted are recognised in revenue.

Cost of sales

Cost of sales comprises expenses for materials and consumables incurred in generating the revenue for the year.

Other external expenses

Other external expenses comprise indirect production costs and leasehold expenses for premises, sales and distribution as well as office expenses, etc.

Staff costs

Staff costs comprise wages and salaries, including holiday allowance, pension and other social security costs, etc., to the Company's employees, excluding reimbursements from public authorities.

Depreciation, amortisation and impairment losses of intangible assets and property, plant and equipment

Depreciation, amortisation and impairment losses comprise the year's amortisation, depreciation and impairment of intangible assets and property, plant and equipment for the year.

Financial income and expenses

Financial income and expenses comprise interest income and expense, gains and losses on transactions denominated in foreign currencies as well as surcharges and refunds under the on-account tax scheme, etc.

Tax on profit for the year

The Parent Company is subject to the Danish rules on compulsory joint taxation of the Group's Danish subsidiaries. The subsidiaries are included in the joint taxation from the date when they are included in the consolidated financial statements and up to the date when they are excluded from the consolidation.

The Parent Company is the administrative company for the joint taxation and accordingly settles all payments of corporation tax to the tax authorities.

Financial statements 1 January – 31 December

Notes

1 Accounting policies (continued)

On payment of joint taxation contributions, current Danish corporation tax is allocated between the jointly taxed entities in proportion to their taxable income. Entities with tax losses receive joint taxation contributions from entities that have used the losses to reduce their own taxable profit.

Tax for the year comprises current corporation tax for the year and changes in deferred tax, including changes in tax rates. The tax expense relating to the profit/loss for the year is recognised in the income statement, and the tax expense relating to amounts directly recognised in equity is recognised directly in equity.

Balance sheet

Intangible assets

Acquired rights and licences

Acquired rights and licences are measured at cost less accumulated amortisation and impairment losses. Rights and licenses are amortised on a straight-line basis over the remaining financial useful life expected to be 5 years.

Goodwill

Goodwill is amortised on a straight-line basis over the estimated useful life determined on the basis of Management's experience within the individual business areas. The maximum amortisation period is between 5 and 25 years and longest for strategically acquired entities with a strong market position and long-term earnings profile.

Development projects

Development costs comprise costs, wages, salaries and amortisation directly and indirectly attributable to development activities.

Property, plant and equipment

Fixtures and fittings, tools and equipment and leasehold improvements are measured at cost less accumulated depreciation and impairment.

Cost comprises the purchase price and any costs directly attributable to the acquisition until the date when the asset is available for use.

The basis of depreciation, which is calculated as cost less any residual value, is depreciated on a straight-line basis over the expected useful life. The expected useful lives are as follows:

Fixtures and fittings, tools and equipment	3-8 years
Leasehold improvements	5-10 years

Gains and losses on the disposal of property, plant and equipment are determined as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains or losses are recognised in the income statement as other operating income or other operating costs, respectively.

Financial statements 1 January – 31 December

Notes

1 Accounting policies (continued)

Impairment of fixed assets

The carrying amount of intangible assets and property, plant and equipment is subject to an annual test for indications of impairment other than the decrease in value reflected by amortisation or depreciation.

Impairment tests are conducted of individual assets or groups of assets when there is an indication that they may be impaired. Write-down is made to the recoverable amount if this is lower than the carrying amount.

The recoverable amount is the higher of an asset's net selling price and its value in use. The value in use is determined as the present value of the expected net cash flows from the use of the asset or the group of assets, including forecast net cash flows from the disposal of the asset or the group of assets after the end of the useful life.

Inventories

Inventories are measured at cost on the basis of weighted average prices. Where the net realisable value is lower than cost, inventories are written down to this lower value.

Goods for resale and raw materials and consumables are measured at cost, comprising purchase price plus delivery costs.

The net realisable value of inventories is calculated as the sales amount less costs of completion and costs necessary to make the sale and is determined taking into account marketability, obsolescence and development in expected selling price.

Receivables

Receivables are measured at the lower of amortised cost and net realisable value, which corresponds to nominal value less write-downs for bad debt losses.

Write-down is made for bad debt losses where there is an objective indication that a receivable has been impaired. If there is an objective indication that an individual receivable has been impaired, write-down is made on an individual basis.

The Company's day-to-day cash resources in the form of deposits with the Group's cash pool scheme are classified as receivables from group entities.

Prepayments

Prepayments comprise costs incurred in relation to subsequent financial years.

Financial statements 1 January – 31 December

Notes

1 Accounting policies (continued)

Equity

Reserve for development costs

The reserve for development costs comprises capitalised development costs. The reserve cannot be used for dividends, distribution or to cover losses. If the recognised development costs are sold or in other ways excluded from the Company's operations, the reserve will be dissolved and transferred directly to the distributable reserves under equity. If the recognised development costs are written down, the part of the reserve corresponding to the write-down of the development costs will be reversed. If a write-down of development costs is subsequently reversed, the reserve will be re-established. The reserve is reduced by amortisation of capitalised development costs on an ongoing basis.

Dividends

Proposed dividends are recognised as a liability at the date when they are adopted at the annual general meeting (declaration date). The expected dividend payment for the year is disclosed as a separate item under equity.

Corporation tax and deferred tax

Current tax payable and receivable is recognised in the balance sheet as tax computed on the taxable income for the year, adjusted for tax on the taxable income of prior years and for tax paid on account.

Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax value of assets and liabilities based on the planned use of the asset or settlement of the liability. However, deferred tax is not recognised on temporary differences relating to goodwill non-deductible for tax purposes and on office premises and other items where the temporary differences arise at the date of acquisition without affecting either profit/loss or taxable income.

Deferred tax assets, including the tax value of tax loss carryforwards, are recognised at the expected value of their utilisation within the foreseeable future; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Any deferred net assets are measured at net realisable value.

Deferred tax is measured in accordance with the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Changes in deferred tax as a result of changes in tax rates are recognised in the income statement or equity, respectively.

Liabilities

Other liabilities are measured at amortised cost.

Financial statements 1 January – 31 December

Notes

DKK'000	<u>2022</u>	<u>2021</u>
2 Revenue		
Domestic	713,567	773,533
Exports	<u>14,063</u>	<u>12,568</u>
Total revenue	<u><u>727,630</u></u>	<u><u>786,101</u></u>
3 Staff costs		
Wages and salaries	101,424	95,293
Pensions	8,331	7,689
Other social security costs	<u>1,888</u>	<u>1,639</u>
	<u><u>111,643</u></u>	<u><u>104,621</u></u>
 Average number of full-time employees	 <u><u>194</u></u>	 <u><u>177</u></u>
 in 2022, one member of the Executive Board received remuneration. In accordance with the Danish Financial Statements Act 98b(3) (ii), the remuneration will not be disclosed separately.		
The board of Directors did not receive any remuneration in 2022 and 2021.		
4 Depreciation, amortisation and impairment losses		
Depreciation on intangible assets	4,744	2,957
Depreciation on property, plant and equipment	<u>3,252</u>	<u>3,369</u>
	<u><u>7,996</u></u>	<u><u>6,326</u></u>
Which breaks down as follows:		
Customer relations	4,744	665
Goodwill	0	2,292
Fixtures and fittings, tools and equipment	2,766	2,964
Leasehold improvements	<u>486</u>	<u>405</u>
	<u><u>7,996</u></u>	<u><u>6,326</u></u>

Depreciation related to Acelity pumps is placed under cost of sales.

Financial statements 1 January – 31 December

Notes

DKK'000	<u>2022</u>	<u>2021</u>
5 Financial income		
Other financial income	1,827	2,104
Exchange gains	797	168
Gain on disposal of financial instruments	<u>660</u>	<u>2,409</u>
	<u>3,284</u>	<u>4,681</u>
6 Financial expenses		
Other financial costs	24	24
Exchange losses	116	-15
Loss on disposal of financial instruments	<u>610</u>	<u>770</u>
	<u>750</u>	<u>779</u>
7 Tax on profit for the year		
Current tax for the year	12,895	10,502
Deferred tax for the year	-160	6,898
Adjustment of tax concerning previous years	<u>1,624</u>	<u>0</u>
	<u>14,359</u>	<u>17,400</u>
8 Proposed profit appropriation		
Reserve for development costs	9,025	16,947
Proposed dividends for the year	50,000	42,000
Retained earnings	<u>-19,382</u>	<u>419</u>
	<u>39,643</u>	<u>59,366</u>

Financial statements 1 January – 31 December

Notes

9 Intangible assets

DKK'000	Customer relations	Goodwill	Development projects in progress	Total
Cost at 1 January 2022	24,936	179,413	29,862	234,211
Additions for the year	0	850	11,571	12,421
Cost at 31 December 2022	24,936	180,263	41,433	246,632
Amortisation and impairment losses at 1 January 2022	-23,275	-143,373	0	-166,648
Amortisation for the year	-666	-4,079	0	-4,745
Amortisation and impairment losses at 31 December 2022	-23,941	-147,452	0	-171,393
Carrying amount at 31 December 2022	995	32,811	41,433	75,239

Development projects in progress

Development projects in progress relates to a new IT-system.

10 Property, plant and equipment

DKK'000	Fixtures and fittings, tools and equipment	Leasehold improvements	Property, plant and equipment in progress	Total
Cost at 1 January 2022	99,714	8,854	2,892	111,460
Additions for the year	5,510	1,404	2,744	9,658
Transfers for the year	2,892	0	-2,892	0
Cost at 31 December 2022	108,116	10,258	2,744	121,118
Depreciation and impairment losses at 1 January 2022	-92,571	-6,651	0	-99,222
Depreciation for the year	-2,766	-486	0	-3,252
Depreciation and impairment losses at 31 December 2022	-95,337	-7,137	0	-102,474
Carrying amount at 31 December 2022	12,779	3,121	2,744	18,644

Financial statements 1 January – 31 December

Notes

DKK'000	<u>31/12 2022</u>	<u>31/12 2022</u>
11 Deferred tax		
Deferred tax at 1 January	-536	-7,434
Deferred tax adjustment for the year in the income statement	<u>-160</u>	<u>6,898</u>
	<u><u>-696</u></u>	<u><u>-536</u></u>

Deferred tax primarily relates to trade receivables.

12 Prepayments

Prepayments of DKK 143 thousand (2021: DKK 66 thousand) comprise costs incurred in relation to subsequent financial years.

13 Cash pool

The Company's day-to-day cash resources in the form of deposits with the Group's cash pool scheme amount to DKK 96,728 thousand and are classified as receivables from group entities.

14 Equity

The share capital consists of 50,100 shares of a nominal value of DKK 100 each. No shares carry special rights.

From 2010-2012, the share capital was unchanged and amounted to nominally DKK 5,000 thousand. Due to a legal merger between Mediq Danmark A/S and Mediq Danmark Køge A/S, the share capital was increased to nominally DKK 5,010 thousand in 2013.

15 Contractual obligations, contingencies, etc.

The Company is jointly taxed with the Danish parent company, Mediq Holding Danmark ApS. The companies included in the joint taxation have joint and unlimited liability for Danish corporation taxes and withholding taxes on dividends, interest and royalties.

The Company is together with the parent company and other group companies jointly and severally liable for credit facilities obtained by the parent company at an amount of DKK 44,6 million (EUR 6 million) as at 31 December 2022.

Operating lease obligations

The Company is subject to an interminable leasehold contract and lease car commitments until 31 August 2026 with obligations totalling DKK 31,701 thousand (2021: DKK 36,295 thousand).

Financial statements 1 January – 31 December

Notes

16 Related party disclosures

Mediq Danmark A/S' related parties comprise the following:

Control

Mediq Holding Danmark ApS, Kornmarksvej 15 - 19, 2605 Brøndby.

Mediq Holding Danmark ApS holds the majority of the contributed capital in the Company.

Financial figures for Mediq Danmark A/S are included in the consolidated financial statements of Mediq Top Holding B.V., which is the smallest and largest group, in which the Company is included as a subsidiary.

The consolidated financial statements of Mediq Top Holding B.V. can upon request be obtained from the Dutch Chamber of Commerce.

Related party transactions

DKK'000	2022	2021
Sale of goods and services to associated companies	9,187	8,849
Purchase of goods and services from associated companies	47,361	51,210

Receivables and debt against group companies are disclosed in the balance sheet.

17 Financial Instruments

The Company has been hedging forecast currency risks relating to the sale and purchase of goods within a year (rolling 12 months) using forward exchange contracts. At 31 December 2022, an amount of DKK 69 thousand is recognised as other receivables, corresponding to the fair value of the 24 contracts that are open at year-end (2021: DKK 923 thousand as other payables, 24 contracts). 12 contracts are in USD and 12 contracts are in CHF.